What can this Peoria joint guide tell me?

What do the medical sources mean for me?

The sources support the basic facts about joint soreness, blood shots, and warning signs. They can't name the cause of your soreness or promise a result.

Results for one joint may not fit another joint or a different kind of damage. Ask whether the people studied had the same sore area and received the same care.

Your doctor can compare those facts with your exam, X-rays, health, and past care. That talk matters more than a broad claim about every sore joint.

Why does QC Kinetix appear here?

The owners of the QC Kinetix clinics serving the Phoenix area operate this publication. That connection gives them a business reason to invite you to a consultation, so it belongs in clear view.

QC Kinetix calls its blood-based shots regenerative treatments, a label that doesn't promise new tissue. Staff draw and spin your blood, then a medical provider may place the platelet-rich part into the sore area.

A medical provider means the licensed medical worker who examines you. Ask whether that person is a doctor, who gives the shot, and what short-term soreness may follow.

What can't this guide decide for me?

This guide can't diagnose your soreness, review your medicines, or choose a procedure for you. It also can't promise how much relief you'll get or how long it may last.

Clinic details and drive times can change, so confirm them while booking. Get the full price, follow-up needs, and activity limits in writing before agreeing.

Urgent warning signs need medical care instead of an office consultation. Those include major trauma, sudden weakness, or fever with a hot and swollen joint.

Sources

1. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation.

   Viswanathan S, et al. — Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019. DOI: 10.1016/j.jcyt.2019.08.002.

2. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.

3. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

4. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

5. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

   United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.